The Patent Finder

MediciNova, Inc.

32 patents currently held · Updated Nov 18, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

8
Ending by 2030
Jun 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Feb 25 to 27, 2027 · next Feb 25
  • 1 fee due Jul 9, 2027
    The maintenance fee for Ibudilast oral formulations and methods of using same (US 11,865,214) comes due Jul 9, 2027. Unpaid by Jan 10, 2028, it lapses early.
  • 1 fee due Sep 12, 2027
    The maintenance fee for Methods of treating chemical gas exposure (US 11,925,625) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
  • 2 fees due Oct 2 to 19, 2027 · next Oct 2

Which patents, and when each one lapses · Pro

Recent changes

  • 2 of the patents on this record were granted since Aug 20, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 7,585,875Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,338,453Treatment of progressive neurodegenerative disease with ibudilast
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,083,713Treatment of progressive neurodegenerative disease with ibudilast
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,944,607Treatment of progressive neurodegenerative disease with ibudilast
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,314,452Treatment of amyotrophic lateral sclerosis (ALS) with ibudilast
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,114,136Treatment of progressive neurodegenerative disease with ibudilast
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,138,201Treatment of progressive neurodegenerative disease with ibudilast
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,420,697Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,518,995Methods and compositions for the treatment of irritable bowel syndrome
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,633,324Denibulin di-hydrochloride
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 32 patents shown.
Pro members see all 32.
Pro members: see all 32 patents
Also on record, not counted in the 32: 1 patent in force now held by others · 2 lapsed for an unpaid fee · 9 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 1 abandoned · 27 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited